Last reviewed · How we verify
NCT03301012: SARC-YA
Smartphone Addiction Recovery Coach for Young Adults (SARC-YA) Experiment
NA trial testing Recovery support as usual in Substance Use Disorders in 237 participants. Completed in 31 May 2024.
31 May 2024
Quick facts
| Lead sponsor | Chestnut Health Systems |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 237 |
| Start date | 30 October 2020 |
| Primary completion | 31 May 2024 |
| Estimated completion | 31 May 2024 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Recovery support as usual
- Smartphone assisted relapse prevention
Conditions studied
- Substance Use Disorders — all drugs for Substance Use Disorders →
Sponsor
Chestnut Health Systems
Who can join
Adults 18 to 26, any sex, with Substance Use Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
At discharge from outpatient treatment, researchers will recruit 300 young adults and randomly assign them to recovery support as usual control condition or the Smartphone Addiction Recovery Coach for Young Adults (SARC-YA) experimental condition. Participants in the experimental conditions will receive a smartphone, a calling/texting/data plan, and the SARC-YA mobile applications for the first 6 months post treatment discharge. Experimental participants will 1) complete a 2-3 minute recovery-focused ecological momentary assessment (EMA) at 5 random times a day, receive feedback on their current answers, and provided access to behavioral charting of their past answers over time; and 2) receive continuous access to a suite of self-initiated ecological momentary interventions (EMI) to support their recovery via tool box of coping tools, apps related to getting support, and apps related to maintaining a healthy lifestyle. Data include standardized assessments, urine tests, mobile phone metadata, EMA responses, and EMI utilization. The study's primary aim and hypothesis are: Aim 1: Test the effects of experimental assignment on the frequency of substance use. H1 Relative to the control group, participants in the experimental group will have lower scores on the quarterly Substance Frequency Scale (3, 6, 9 months post- discharge).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03301012
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Substance Use Disorders
Currently open trials in the same condition.
- NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
- NCT07529327 — Prevent Language Delays and Disorders Among Children of Caregivers With Substance Use Disorders With Community Groups an · NA · recruiting
- NCT07281261 — tAN for Substance Use Disorder · NA · recruiting
- NCT07210268 — Temporal Interference Methods for Addiction Treatment · NA · recruiting
- NCT07146633 — Efficacy of an EMDR App for PTSD and SUD · NA · recruiting
Other Chestnut Health Systems trials
Trials by the same sponsor.
- NCT06375551 — K-ORCA: Testing a Decision Support Tool and Group Process for Selecting Interventions · NA · recruiting
- NCT07365293 — Testing Implementation Strategies to Scale-up a Multicomponent Continuum of Service Intervention for Families Involved i · NA · recruiting
- NCT07218562 — PATH (Peer Advanced Training in Harm Reduction) to Reducing Burnout Among Peers Who Deliver Harm Reduction Services (R61 · Phase 2 · enrolling by invitation
- NCT06852170 — Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prev · NA · recruiting
- NCT06414993 — Leveraging Parents and Peers to Increase Recovery Capital in Emerging Adults · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03301012 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chestnut Health Systems
- Last refreshed: 30 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03301012.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing